

**An Anti-VEGFR2/Flk-1 *Listeria monocytogenes* Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu Positive Breast Tumors in a Mouse Model<sup>6</sup>**

Matthew M. Seavey<sup>1</sup>, Paulo C. Maciag<sup>1, 2</sup>, Nada Al-Rawi<sup>1, 4</sup>, Duane Sewell<sup>1, 3</sup>, Yvonne Paterson<sup>1,5</sup>

Running title: Anti-Angiogenesis Immunotherapy For Breast Cancer

<sup>1</sup>Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104

<sup>2</sup>Current address: Advaxis, Inc., North Brunswick, NJ 08902

<sup>3</sup>Current address: University of Maryland, 16 S. Eutaw St. Suite 500 Baltimore MD 21201

<sup>4</sup>Current address: Department of Pediatrics, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, 101 Dudley St, Providence, RI 02905

<sup>5</sup>Address correspondence and reprint requests to Dr. Yvonne Paterson, Department of Microbiology, 323 Johnson Pavilion, 36<sup>th</sup> street and Hamilton Walk, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6076. E-mail: [yvonne@mail.med.upenn.edu](mailto:yvonne@mail.med.upenn.edu)

Keywords: *Listeria*, Her-2/neu, immunotherapy, anti-angiogenesis, VEGFR2

<sup>6</sup>This work was supported by grant 5RO1CA109253-03. Matthew Seavey and Nada Al-Rawi were supported by training grant “The immunobiology of normal and neoplastic lymphocytes” T32CA09140.

Abbreviations used in this paper: *Listeria monocytogenes* (*Lm*); Fetal Liver Kinase-1 (Flk-1); Vascular Endothelial Growth Factor Receptor (VEGFR)

## **ABSTRACT (231)**

Thirty years after angiogenesis was shown to play an enabling role in cancer, modern medicine is still trying to develop novel compounds and therapeutics to target the tumor vasculature. However, most therapeutics require multiple rounds of administration and can have toxic side effects. Here we use anti-angiogenesis immunotherapy to target cells actively involved in forming new blood vessels that support the growth and spread of breast cancer. Targeting a central cell type involved in angiogenesis, endothelial cells (ECs), we immunized against host Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) to fight the growth of Her-2/neu+ breast tumors. Using the bacterial vector, *Listeria monocytogenes* (*Lm*), we fused polypeptides from the mouse VEGFR2 molecule (Flk-1) to the microbial adjuvant, Listeriolysin-O (LLO), and used *Lm* to deliver the antigens and elicit potent anti-tumor CTL responses. *Lm*-LLO-Flk-1 was able to eradicate some established breast tumors, reduce microvascular density in the remaining tumors, protect against tumor re-challenge and experimental metastases and induce epitope spreading to various regions of the tumor-associated antigen Her-2/neu. Tumor eradication was found to be dependent on epitope spreading to HER-2/neu and was not solely due to the reduction of tumor vasculature. However, vaccine efficacy did not affect normal wound healing nor have toxic side effects on pregnancy. We show that an anti-angiogenesis vaccine can overcome tolerance to the host vasculature driving epitope spreading to an endogenous tumor protein and drive active tumor regression.

## INTRODUCTION

Targeting host vasculature in an attempt to target chemo-resistant tumors has been a central paradigm and a sought-after therapy in oncology for decades (1). First presented by Folkman and colleagues (2), anti-angiogenic treatment has recently entered the clinic with the successful use of bevacizumab in several cancer types including breast cancer (3). Since then anti-angiogenesis treatments for cancer have multiplied and several products are either in clinical use or trials (4).

Targeting cells involved in angiogenesis cripples rapidly growing tumors by limiting the oxygen and nutrients supply or, depending on the strategy employed, increasing the susceptibility of tumor cells to chemotherapy by enhancing the efficiency of a delivered drug via vascular network reorganization (5, 6). Although originally thought to be unlikely, resistance of tumor cells to anti-angiogenesis treatment has been observed in mouse systems and reported for human studies for several different treatments (7). Additionally, the tumor microenvironment (TME) recruits myeloid-derived suppressor cells (MDSC) that are responsible for the necessary angiogenic switch needed for tumor growth and eventual dissemination (8).

Studies performed by several investigators have repeatedly shown the importance of targeting tumor angiogenesis because of its central role in invasion, growth, and metastasis (9, 10). Since tumor cells frequently mutate in response to therapy or downregulate MHC class I molecules required for T cell-mediated responses, targeting endothelial cells and pericytes, which are essential for tumor survival and may lack the immunosuppressive mechanisms deployed by tumors, would be advantageous. Previously, we have shown that targeting pericytes in breast tumors, using an immunotherapy against the chondroitin sulfate molecule, high molecular weight melanoma-associated antigen (HMWMAA), results in lower pericyte coverage of tumor blood vessels, which leads to tumor cell death (11). In this report, we use the potent, live vaccine vector, *Listeria monocytogenes*, to overcome tolerance to mouse Flk-1/VEGFR2 and, indirectly, to Her-2/neu.

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is thought to be expressed on the luminal surface of activated or proliferating endothelial cells (ECs) and participates in the formation of new blood vessels (12). It's the first endothelial receptor known to be expressed on the primitive mesoderm (13). VEGFR2 is highly expressed on endothelial cells (14). Strong induction of VEGFR2 is involved in the neovascularization of various human or experimental tumors (15). VEGFR2 binds all 5 isoforms of VEGF. Signaling of VEGF through VEGFR2 on ECs induces proliferation, migration, and eventual differentiation. The mouse homologue of VEGFR2 is the fetal liver kinase gene-1 (Flk-1), which is a strong therapeutic target (16, 17), and has important roles in tumor growth, invasion, and metastasis (18, 19). Several approaches have been used to block Flk-1 including dominant-negative receptor mutants, germ-line disruption of VEGFR genes, monoclonal antibodies (Mabs) against VEGF and a series of synthetic receptor tyrosine kinase (RTK) inhibitors (20, 21). Immunotherapeutic strategies have included targeting VEGFR2 using DNA vaccines delivered orally by *Salmonella typhimurium* (16). We have attempted to modify this approach by expressing three fragments of the VEGFR2 molecule fused to the microbial adjuvant listeriolysin-O (LLO) and expressed in *Listeria monocytogenes*.

*Listeria monocytogenes* is a gram-positive facultative intracellular bacterium able to infect phagocytic cells (22) and whose life cycle makes it a valuable delivery vehicle for foreign proteins. After phagocytosis, *Lm* escapes the phagosome via the hemolytic virulence factor LLO, encoded by the *hly* gene, to replicate in the cytoplasm. Routinely, we engineer *Lm* to express our gene of interest fused to the first 441 amino acids so as to exclude the hemolytic domain of this protein (22-24). LLO contains a PEST domain that is important for the adjuvant activity in the fused proteins (25).

The use of *Listeria monocytogenes* as a vaccine vector has shown promise for several different diseases (26). Our lab (23, 24, 27, 28), as well as others (29-31), have repeatedly shown that *Listeria* can efficiently immunize mice against tumor proteins and overcome self-tolerance, and that it is safe for use in humans (32) (Rothman et al, unpublished clinical data). We show here that immunizing against the breast tumor

vasculature leads to epitope spreading and immunity to Her-2/neu, which is required for tumor regression. Unlike several previous reports that also used VEGFR2 immunotherapy to target the tumor vasculature, here we describe a novel method of targeting both the tumor vasculature and an endogenous tumor antigen (Her-2/neu) using a single vaccine.

## **MATERIALS AND METHODS**

### ***Mice.***

Female FVB/N mice were purchased from Charles River Laboratories. The FVB/N Her-2/neu transgenic mice were housed and bred at the animal core facility at the University of Pennsylvania. Mice were six to eight weeks old when used at the start of the experiments, which were done in accordance with regulations by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

### ***Peptides and Antibodies.***

Anti-mouse CD31, anti-mouse CD8 $\alpha$ -PE, rat IgG<sub>2a</sub>-PE isotype controls were purchased from BD Biosciences (San Jose, CA). Rabbit anti-Listeria antiserum polyclonal antibody, serotypes 1, 4 was purchased from Difco BD Biosciences. Rabbit anti-HIF-1 $\alpha$  was purchased from Novus Biologicals (Littleton, CO). Goat anti-Rabbit-Alexa-488 secondary antibody was purchased from Invitrogen. DAPI was purchased from Sigma (St. Louis, MO). Rat anti-mouse IFN $\gamma$  (clone AN18) was purchased from MABTECH (Mariemont, OH). Rat anti-mouse IFN $\gamma$  (clone XMG1.2) was purchased from eBioscience (San Deigo, CA). The antibodies used in the Western blot for fusion protein expression was either a polyclonal rabbit serum raised to the first thirty residues (PEST) of LLO protein (25) or an anti-LLO mouse antibody, specific for full-length LLO, generated from hybridoma supernatant, clone #B5-19 (33). All peptides were purchased from EZBiolabs (Westfield, IN). Tetramers were provided by Dr. Amy Stout of the National Institutes of Health AIDS Research and Reference Reagent Program. Tetramers used were all PE-conjugated H-2D<sup>q</sup> and contained either peptides for Her-2/neu region EC1 (ASPETHLDML), or EC2 (PDSLRDLSVF) or IC1 (GSGAFGTVYK). Peptides used in these studies were as follows: Flk-E1<sub>210-219</sub> (TYQSIMYIV), Flk-E2<sub>613-622</sub> (MFSNSTNDI), Flk-I1<sub>906-915</sub> (PGGPLMVIV), Flk-I1<sub>839-848</sub> (GRGAFGQVI) (17); Her2-pEC1<sub>302-310</sub> (PYNYLSTEV), Her2-pEC2<sub>420-429</sub> (PDSLRDLSVF), Her2-pIC1<sub>732-741</sub> (GSGAFGTVYK) (24); HIV-pGag (AMQMLKETI) (34).

### ***ELISpots***

Secretion of IFN- $\gamma$  by mouse splenocytes in response to peptide stimulation was tested by enzyme-linked immunospot (ELISpot) assay as previously described (29). We preferred to use ELISpots over other assays because of the level of sensitivity that could be obtained for low frequency, antigen specific cells and also because we could test for anti-Her-2/neu and anti-Flk-1 specific T cells directly *ex vivo* without *in vitro* manipulation. Briefly, isolated splenocytes were plated at  $1 \times 10^6$  cells per well or titrated across a 96 well plate coated with 7  $\mu$ g/ml of rat anti-mouse IFN- $\gamma$  antibody (clone AN18, MABTECH, Mariemont, OH), in the presence of 10  $\mu$ g/ml peptide and 5 U/ml of IL-2. Secondary, biotinylated, anti-IFN $\gamma$  antibody (clone XMG1.2, eBioscience) was added to each well at a final concentration of 2  $\mu$ g/ml. After overnight incubation at 37 C plates were developed for 1 hour at room temperature with Streptavidin-horseradish peroxidase (1:1000 dilution) followed by substrate TMB (Vector laboratories, ABC kit). Spots were counted using the Immunospot C.T.L. scanner and counting software (CTL, Cleveland, OH).

### ***Cell lines.***

Cell culture media and supplements were purchased from Gibco (Invitrogen). NT-2 and J774A.1 cells were maintained as previously described (11). All cell cultures were kept at 37 C and 5% CO<sub>2</sub>. 4T1 and 4T1 cells stably expressing the firefly luciferase gene (4T1-Luc) were the kind gift of Dr. Ellen Pure (Wistar Institute) and were maintained in cell culture medium.

### ***Construction of Lm-LLO-Flk-1 vaccines.***

The source of the Flk-1 gene was a DNA vaccine plasmid generously provided by Dr. Ralph Reisfeld (The Scripps Research Institute, La Jolla, CA). Fragments corresponding to residues 68 to 1081 were amplified by PCR using the following primers: Flk-E1 (F): 5'-GGGCTCGAGCGTGATTCTGAGGAAAGGGTATT-3', Flk-E1 (R): 5'-GGGACTAGTTTACCCGGTTTACAATCTTCTTAT-3', (AA 68-277); Flk-E2 (F): 5'-GGGCTCGAGGTGATCAGGGGTCCTGAAATTA-3', Flk-E2 (R): 5'-GGGACTAGTTTAGCCTCCATCCTCCTTCCT-3', (AA 545-730); Flk-I1 (F): 5'-GGGCTCGAGGAAGGGGAAGTGAAGACAGCC-3', Flk-I1 (R): 5'-

GGGACTAGTTTATGTGTATACTCTGTCAAAAATGGTTTC-3', (AA 792-1081). *Xho*I sequence underlined for forward (F) primer, *Spe*I sequence underlined for reverse (R) primer, stop codon in bold. The PCR product was ligated into pCR2.1-TOPO plasmid (Invitrogen), confirmed by sequencing and subsequently excised by double digestion with *Xho*I and *Spe*I (New England Biolabs). The fragment was ligated into a pGG34-based plasmid downstream and fused to a gene encoding for the first 441 residues of the LLO protein, whose expression is driven by the *hly* promoter. The construction of the pGG34 plasmid has been described in detail elsewhere (28). The resultant plasmid was electroporated into the PrfA-defective *Lm* strain XFL-7, which is derived from the *Lm* strain 10403S. Positive clones were selected on Brain Heart Infusion (BHI, Difco) plates supplemented with 34 µg/ml of chloramphenicol and 250 µg/ml of streptomycin. The resultant strains were named *Lm*-LLO-Flk-E1, *Lm*-LLO-Flk-E2, and *Lm*-LLO-Flk-I1.

#### ***Growth and Preparation of Lm Vaccine Doses***

Vaccine stocks were kept at -80 C in 10% glycerol in 1 X PBS. Each stock was streaked over a chloramphenicol/streptomycin plate and grown overnight. A single colony was used for growth in an overnight culture of 5mls BHI media under antibiotic selection. This culture was further expanded for 4hrs in a shaking incubator at 37 C and grown until the microbial density reached 0.4-0.8 OD<sub>600</sub> at which time the microbes were washed and frozen sterile in 10% glycerol and kept at -80 C until use. Stocks were titered for each lot generated. Single lots were used for one continuous experiment, different lots were used for each repetition, lot-to-lot variation was not observed. Each lot was checked for fusion protein expression by Western Blot with an anti-PEST and anti-LLO antibody. For each dose, one vial is selected, thawed and washed twice in 1X PBS before dilution and use; unused microbes are discarded.

#### ***Effect of Lm-LLO-Flk-1 vaccines on tumor growth***

1 x 10<sup>6</sup> of NT-2 tumor cells were injected s.c. in 200 µl of PBS on the flank of FVB/N mice. On day 4 after tumor inoculation, mice were immunized i.p. with 5 x 10<sup>8</sup> CFUs of either *Lm*-LLO-Flk-E1, *Lm*-LLO-Flk-E2 or *Lm*-LLO-Flk-I1. This dose was determined

as one-tenth of the minimum dose observed to have adverse effects on the mice and was used in all experiments. Immunizations were repeated weekly totaling 3 doses of the vaccine for all experiments. In the control groups, mice received a control *Lm* vaccine – *Lm*-LLO-NY-ESO-1<sub>101-156</sub>. *Lm*-LLO-NY-ESO-1<sub>101-156</sub> acts as an irrelevant or third party *Lm* vaccine to control for immune responses to LLO or the listerial infection, we commonly use this vaccine as a control at comparable concentrations to the test vaccine (35). Tumors were measured every 3 days with calipers and the shortest (width) and longest surface diameters were recorded for each individual tumor. Mice in groups were not blinded for tumor size. Calculated tumor volumes were performed using the following equation: [(width)<sup>2</sup> x length x 0.52]. Mice were sacrificed if they developed open wounds or tumors reached 20 mm in diameter. Tumor-free surviving mice challenged with NT-2 were re-challenged in the opposite flank with the same cell line at least 10 weeks after the first inoculation.

### ***Tumor Immunofluorescence***

On day 64 post-tumor inoculation, mice were sacrificed and the NT-2 tumors were surgically excised, cryopreserved in OCT freezing medium and cryosectioned to provide 8-10mm thick sections. For immunofluorescence, samples were thawed and fixed using 4% formalin. After blocking (2.4G2 conditioned medium/10% FBS/5% normal rat and mouse serum), sections were stained with primary antibodies in blocking solution in a humidified chamber at 37 C for 1 hour. Samples were stained with secondary antibody following the same procedure as used for primary staining. DAPI (Invitrogen) staining was performed according to manufacturer's instructions. Intracellular staining for HIF-1 $\alpha$  was done in PBS/0.1% Tween/1% BSA solution. Slides were cover-slipped using mounting solution (Biomedex) with anti-fading agents, set for 24 hours and kept at 4 C until imaged using Spot Image Software (vs. 2006) and a BX51 series Olympus fluorescent microscope. Images were merged using Spot Image Software and quantitation was performed after an ROI was gated using Image Pro Software (vs. 2006). All images are a merged series of three different channels captured for the same exposure time. For the quantitation of microvascular density using anti-CD31 we based our

analysis on previously published works using similar strategies for measuring MVD in mouse tumor models (36-38).

### ***Metastasis studies and Bioluminescent Imaging***

Mice were given a total of three vaccinations prior to i.v. injection, 7 days post-final vaccination, with 50,000 4T1 cells expressing the integrated luciferase reporter gene (4T1-Luc). The corresponding substrate, D-Luciferin was injected i.p. at 5-10 mg/mouse in 200ul of PBS before imaging. The mice were placed in the dark chamber of a Xenogen IVIS imaging system (X-100) (Xenogen Corporation, Alameda, CA), under anesthesia following i.p. injection of ketamine (80mg/kg)/xylazine (12mg/kg) (Sigma, St. Louis, MO). Photographic and luminescence images were captured with a CCD camera and the luminescence intensity was quantitated using Living Image software (version 2.11) from Xenogen according to the manufacturer's instructions. Longitudinal imaging was performed on a weekly basis until at least 4 weeks post tumor inoculation. All mice were imaged for the same exposure and length of time. Images show normalized graphics. For the pathology study, the identical experiment was performed except lung tissue was perfused, extracted, wax embedded and stained with H+E before being counted (by hand) for tumors.

### ***Pregnancy and wound healing safety studies.***

Six to eight week old FVB/N female mice were immunized three consecutive times weekly with either a control *Lm* vaccine or *Lm*-LLO-Flk-1 vaccines. On the fourth week safety studies were conducted. For pregnancy and fertility, 5 mice per group were allowed to mate with individually housed males. Coitus was monitored and confirmed by the presence of a vaginal plug. Time to gestation, pup weight at birth and total litter size were measured. The wound-healing assay utilized in this study was done according to previously described methods (11, 16). Briefly, mice were anesthetized, hair removed and skin-cleaned with an aseptic wipe. Two circular 3mm in diameter wounds were punched from the skin using a sterile skin biopsy tool (Acuderm). Wounds were not treated and no infection was observed. Average time to wound closure was monitored and considered complete when a scar was formed without any visible scab left.

***Statistical analysis and methods of quantitation.***

Data were analyzed using the non-parametric Mann-Whitney test. The log-rank chi-squared test was used for all survival data. All statistical analysis was done with Prism software, vs. 4.0a (2006). Statistical significance was based on a value of  $p \leq 0.05$ . In all non-transgenic studies we included at least 8 mice per group. All studies were repeated at least once.

## RESULTS

A total of three constructs were tested, each containing a different region of Flk-1: E1 (AA 68-277), E2 (AA 545-730) and I1 (792-1081) (Figure 1A). Regions were selected based on predicted epitopes. Since we were interested in testing these vaccines in the FVB/N-based breast cancer model, we decided to clone fragments that would be most appropriate for the model haplotype used for testing (i.e., FVB/N, H2<sup>q</sup>). The E1, E2 and I1 domains selected contained several potential epitopes for the H-2<sup>q</sup> mouse MHC I haplotype (Figure 1A, Flk<sub>210</sub> (TYQSIMYIV), Flk<sub>613</sub> (MFSNSTNDI), Flk<sub>906</sub> (PGGPLMVIV) (17, 24).

Each fragment was cloned as a fusion protein with the truncated LLO protein (Figure 1B). To test whether the LLO-Flk-1 fusion proteins were produced and secreted by the *Lm*-LLO-Flk-1 constructs, we analyzed protein from culture supernatants by Western-Blot (Figure 1C) using a polyclonal anti-PEST antibody (Figure 1C bottom) or anti-LLO antibody (Figure 1C top). A band for each fusion construct was detected, LLO-Flk-E1, LLO-Flk-E2, and LLO-Flk-I1, each calculated from amino acid molecular weight to be around 81-, 78- and 89-kDa respectively. Several of the bands do not correlate exactly with the calculated molecular size, however, this is common and has been observed for other, similar vaccine constructs (24). The band around 60-70 kDa is endogenous LLO; the truncated fusion protein LLO is found around 60-50 kDa (39). The anti-LLO blot was used as a control to show that our fusion proteins are LLO-Flk linked. All three constructs were able to infect, grow, and escape the phagolysosome as evidenced by replication in J774A.1 macrophages (Figure S1). Also, each vaccine was able to immunize mice against cloned Flk-1 regions as shown by IFN $\gamma$  splenocyte responses *ex vivo* (Figure 1D). Peptides used for re-challenge in these FVB/N ELISpot experiments were originally mapped in the H2<sup>d</sup> Balb/c mouse as immunodominant Flk-1 epitopes (17). We routinely use H2<sup>d</sup> mapped epitopes in H2<sup>q</sup> models as H2<sup>d</sup> identified epitopes can also serve as H2<sup>q</sup> epitopes (39-41), presumably due to the high homology of the H2<sup>d</sup> and H2<sup>q</sup> molecules (42).

### ***Therapeutic efficacy of Lm-LLO-Flk-1 vaccines in a Her-2/neu-expressing tumor model***

To test the ability of our vaccines to induce the regression of Her-2/neu<sup>+</sup> breast tumors, we used the NT-2 tumor model, which overexpresses the rat Her-2/neu as a transgene and was originally derived from a spontaneous mammary tumor in the FVB/N Her-2/neu transgenic mouse (43). The NT-2 cell line does not express the Flk-1 molecule (44), and thus our antigen of interest is only located on the host vasculature. Cells were grown *in vitro* and transplanted subcutaneously into the flank of FVB/N mice. On day 4, when palpable (~4-5mm in diameter) tumors had formed, mice were vaccinated and then boosted weekly for a total of three vaccinations. Vaccines Flk-E1 and Flk-I1 were able to induce regression, and in some mice complete eradication (Flk-E1: 2/8; Flk-I1: 2/8) of transplanted tumors by day 64 post-inoculation (Figure 2A). However, Flk-E2 was unable to control tumor growth, which was similar to the group treated with the control *Lm*. Mice with completely regressed tumors were re-challenged with NT-2 on the contralateral side at 100 days post-tumor inoculation and re-growth of the new tumor was not observed suggesting long-lived anti-tumor immunity (Figure 2C and 2D).

Microvascular density (MVD) of day 64 tumors was assessed by staining with the pan-endothelial cell marker CD31 and counterstained with the nuclear marker DAPI. As expected, MVD in tumors from the Flk-E2 treated group resembled those from control treated mice. However, a reduction in the density of CD31<sup>+</sup> vessels was seen in Flk-I1 treated mice and a further reduction was observed using the Flk-E1 vaccination (Figure 2E). This reduction in CD31<sup>+</sup> vessels correlated with an increase in staining for the nuclear hypoxic marker, Hypoxia Inducible Factor-1 $\alpha$  (HIF-1 $\alpha$ ) in the Flk-E1 and Flk-I1 treated groups, but not for the control group (data not shown). It is possible to hypothesize that regression of these Her-2/neu<sup>+</sup> tumors, in addition to the reduction of tumor MVD, was due to anti-VEGFR2 cytotoxic T cells killing endothelial cells involved in tumor angiogenesis, possibly leading to tumor damage or growth restriction resulting in the observed regression. Subsequently, phagocytosed tumor debris could be cross-presented by local dendritic cells in draining lymph nodes and presented to anti-Her-

2/neu CTLs, whose epitopes have been previously mapped in the FVB/N mouse (24, 39-41). If this inter-molecular epitope spreading occurred, we would expect that mice that exhibited the greatest regression would also have a high frequency of anti-Her-2/neu CD8<sup>+</sup> T cells. To test this hypothesis, we harvested splenocytes from day 64 mice, and performed an IFN $\gamma$  ELISpot, re-challenging with three known epitopes from three different regions of Her-2/neu (24). We decided to use an ELISpot assay to measure anti-Her-2/neu responses because we had previously mapped CTL epitopes for different regions of the Her-2/neu molecule and the ELISpot assay is sensitive enough to detect a low frequency of specific T cells, unlike several cytotoxic assays that require in vitro stimulation and expansion. We found that Flk-E1 and Flk-I1 showed the greatest epitope spreading, while Flk-E2 showed the least (Figure 2B, \*p<0.05), strongly correlating with the extent of tumor regression found *in vivo* (Figure 2A).

***Anti-angiogenesis induced tumor regression is dependent on epitope spreading to an endogenous tumor antigen***

The presence of Her-2/neu epitope spreading suggested that tumor regression may not solely depend on anti-vascular events, but also on the immune response to the tumor antigen HER-2/neu. To test this hypothesis we repeated the same experiment using the two most potent vaccines, Flk-E1 and Flk-I1 but, in addition to inoculation of wild-type FVB/N mice, we also injected the NT-2 cells subcutaneously into its syngeneic progenitor strain, FVB/N Her-2/neu transgenic, which exhibits profound tolerance to the rat Her-2/neu molecule (41, 43). Again, Flk-E1 and Flk-I1 slowed the growth of the NT-2 tumors in wild type FVB/N mice, as previously demonstrated, (Figure 3A, left panel), however, in the transgenic host where anti-HER-2/neu responses are limited by tolerance, we observed outgrowth of all tumors (Figure 3A, right panel). Both these results reflected the epitope spreading observed towards the endogenous Her-2/neu protein demonstrated in the spleen (Figure 3B) and at the tumor site as shown for the Flk-E1 vaccination (Figure 3C). This suggests that anti-vascular events are not enough for tumor regression, but rather the combined effect on both the tumor's vasculature and directly on tumor cells is required for tumor death and ultimately regression.

***Vaccination with *Lm-LLO-Flk-1* vaccine fragments can prevent the growth of experimental metastases***

An important use for anti-angiogenesis vaccines could be for the treatment or prevention of breast cancer metastasis. Tumor cells that metastasize are highly dependent on the development of new vessels, although smaller tumors do not completely rely on new vasculature (45). However, it has been hypothesized that once they have grown beyond a certain size, tumors become highly dependent on the formation of new vessels (46) and thus become a possible target for anti-VEGFR2 CTLs. To test if our vaccines could protect against breast tumor dissemination we used an experimental metastasis system involving the direct inoculation of *in vitro* cultured tumor cells into the tail vein of mice allowing for rapid colonization of several downstream organs, especially the lung (47). Since after tail vein vaccination, the NT-2 model does not well colonize the lung (data not shown) we used 4T1, which is an aggressive, mouse breast carcinoma cell line from the Balb/c mouse. Balb/c mice were immunized thrice over the course of three weeks with either *Lm-LLO-Flk-E1*, or *Lm-LLO-Flk-I1* or a control *Lm* vaccine. Mice were then injected with 50,000 4T1 cells i.v. and also s.c. within the same animal. The s.c. site injection was performed so that we could measure primary tumor growth, while the i.v. injection mimicked metastasis. Mice treated with the Flk-1 vaccines had reduced primary s.c. tumor growth rate (Figure 4D). Unlike the poor responses seen against the primary 4T1 tumor, the rate of seeding and total metastases found in each animal was significantly lower in treated animals compared to control treated mice (Figure 4A). We observed a low level of epitope spreading to Her-2/neu (Figure 4B), probably because 4T1 weakly expresses the mouse Her-2/neu (48).

To more stringently test the hypothesis that immunizing against Flk-1 can prevent the seeding of lung tissue with experimental metastases, we used a bioluminescent model where individual tumor cells and masses can be visualized using non-invasive imaging. Mice were injected i.v. with 50,000 4T1 cells expressing the firefly luciferase gene (4T1-Luc) after several rounds of vaccination with the *Lm-Flk-E1* and *-I1* vaccines. On a weekly basis, mice were anesthetized and injected with a luciferase substrate (D-

Luciferin) and imaged. Lung seeding was apparent by day 11 and control treated mice rapidly become colonized with 4T1-Luc cells by day 25 whereas none of the *Lm*-LLO-Flk-E1 and *Lm*-LLO-Flk-I1 treated mice showed any signs of lung seeding until at least day 32 at which point the control treated mice had become ill and were sacrificed (Figure 4C). At day 32, only 25% of the Flk-1 vaccinated mice showed any lung tumors. It is possible that tumor masses were undetectable at this time point by this bioluminescent method since a signal for tumor cells was observed on day 25 but not day 32 for the *Lm*-Flk-E1 treated group. This very small signal on day 25 is below the 1000 cell threshold and may have lost some cellular mass within the following week to fall below the limit of detection for the system. Mice immunized with the control *Lm* rapidly became diseased by lung tumors, but the Flk-E1 and Flk-I1 *Lm* vaccinations delayed tumor burden, time to progression (day 25 for control treated versus day 32 for Flk-1 treated), and eventual disease (data not shown).

***Immunization with Flk-1 has no impact on wound healing, pregnancy or fertility in mice***

To evaluate whether *Lm*-LLO-Flk-1 vaccines cause toxicity that is associated with angiogenesis inhibition, we studied wound healing, pregnancy and fertility in immunized mice. Mice were immunized thrice with *Lm*-LLO-Flk-E1, *Lm*-LLO-Flk-E2, *Lm*-LLO-Flk-I1, control *Lm* or saline alone before being mated or given sterile wound punches. We observed mice that were mated for length of gestation from coitus, mean pup mass at term, and total litter size. Wound punches were sterile but mice were caged together. Wound healing technique was followed according to previously described methods (16). Five mice from each immunization group were shaved and given sterile wound punches, two per animal then allowed to heal over time. Time to wound closure was measured. Full wound healing was considered complete, no scabs were left at time of wound closure. Immunization with *Lm*-LLO-Flk-E1, *Lm*-LLO-Flk-E2, or *Lm*-LLO-Flk-I1 had no impact on fertility, gestation length or pup mass at birth (Figure 5A). Similarly, immunization had no significant impact on the time required for wound closure (Figure 5B).

## DISCUSSION

The advantage of using *Listeria monocytogenes* to deliver a self protein fused to the microbial adjuvant LLO is that we are able to overcome tolerance to VEGFR2 on host endothelial cells as well as generate an immune response to the rat Her-2/neu endogenous tumor antigen found on transplanted tumor cells. Driving immune responses to a defined tumor antigen expressed by the tumor cells via the indirect targeting of the tumor vasculature, is a novel finding, and warrants additional investigation for the manipulation and benefit of this vaccination strategy.

The Flk-E1 and Flk-I1 vaccinations were the most effective and could induce the greatest regression, MVD reduction, and epitope spreading in NT-2 tumor models. In contrast, although the Flk-E2 vaccination could generate strong immune responses *in vivo* against Flk antigens, it failed to induce the regression of NT-2, which led to poor epitope spreading and vascular destruction (Figure 2). It is possible that the Flk-E2 vaccine is generating weakly cytotoxic CTLs; this has yet to be tested. The reduced vaccine efficacy of Flk-E2 is unlikely to be due to differences between the expression of the fusion protein by the vaccines as all three vaccines have similar expression levels (Figure 1B). However, the presence of intact tumor vessels in Flk-E2 vaccinated mice (Figure 2E) suggests that targets are being spared, thus CTLs are either being generated at a very low frequency, or the cells that are being generated are of low avidity. Another possibility is that Flk-E2 could be inducing T-regulatory cells as has been shown for previous vaccines (23), which hinder cytolytic function of anti-tumor CD8<sup>+</sup> T cells *in vivo*.

Another possible reason for the poor performance of the Flk-E2 vaccine could be that Flk-E1 and Flk-I1 share regions of homology with Her-2/neu that Flk-E2 fragments do not. Her-2/neu is part of the EGFR family, which is related to the VEGFR family (49). The overall protein homology between mouse Flk-1 and rat Her-2-neu is fairly low (5.37%); they primarily share sequence identity in the protein kinase signaling domain. Homology between Flk-E1 and rat Her-2/neu is non-existent, thus for this vaccine it

seems highly unlikely that anti-Her-2/neu responses do not arise by epitope spreading. The greatest level of homology between Flk-I1 and the kinase domains of Her-2/neu are 41% with a 168AA-long stretch in rat Her-2/neu, AA 817-983, and 22% in a 200AA-long stretch at AA 627-821, both which we have previously mapped for Her-2/neu and identified several CTL epitopes (41). Within these sequences we found similarities in Flk-1 with only two of the known Her-2/neu epitopes: the mouse Flk-1 sequence: KICDFGLARD (AA 1041-1050) is similar to the rat Her-2/neu epitope: KITDFGLARL (AA 861-870); and the mouse Flk-1 sequence: GRGAFGQVI (AA 839-848) is also similar to the rat Her-2/neu epitope: GSGAFGTVYK (AA 732-741). Missing homology is underlined, mutations that result after immunization with anti-Her-2/neu *Lm* vaccinations are in bold (39). However, a RANKpep analysis shows that the mouse Flk-I1<sub>839-848</sub> is the only likely epitope (<http://mif.dfci.harvard.edu/Tools/rankpep.html>, analysis not shown). We thus tested if immunization of FVB/N mice with Flk-I1 vaccine could induce immunity to FLK-I1<sub>839-848</sub>, which is cross-reactive to the rat Her-2/neu epitope GSGAFGTVYK. Vaccination of mice with *Lm*-LLO-Flk-I1 lead to excellent responses against the previously mapped Flk-I1 epitope PGGPLMVIV (17) however no significant responses were seen against either the mouse Flk-I1<sub>839-848</sub> epitope or the homologous rat Her-2/neu IC1<sub>732-741</sub> epitope (Figure 6). Thus the immune responses to Her-2/neu observed after Flk-I1 immunization were most likely due to epitope spreading and not due to cross-reactivity between shared epitopes. However, we cannot definitely say that cross-reactivity to Her-2/neu shared domains is not occurring, rather the likelihood of this event seems very low.

The finding that an anti-angiogenesis vaccine induces secondary anti-tumor responses that are crucial to its efficacy is novel and opens the door for several possible vaccination strategies that harness the power of this epitope spreading phenomenon. To extend on this observation - an interesting possibility would be to boost the secondary anti-Her-2/neu response generated at an additional time point after therapy. We suspect that this would provide additional protection from residing tumor cells, or tumor stem cells, as Her-2/neu is also highly expressed on these cell types (50).

A difficulty encountered in targeting the vasculature of tumors is that when vessels are destroyed current or additional therapy is unable to reach the tumor. Hypoxic areas of the tumor may become difficult to treat after anti-angiogenic therapy, however, tumors over express survival factors, mutate check-point proteins like p53, and constitutively express certain hypoxia-induced genes that allow tumors to become resistant to such conditions. The current theory of how anti-angiogenesis treatment functions is that tumor vessels become reorganized to a more 'normal' infrastructure allowing for the efficient delivery of treatment (6). However, the MVD loss observed in this study, suggests that vessel integrity is nearly completely lost and is strongly associated with regressing tumors. However, it appears that tumor-specific TILs can enter the tumor and remain in the tissue weeks post vaccination (Figure 3C). Thus, disruption of the tumor vasculature either is not enough to reduce TIL trafficking or the influx of immune cells occurs before the disintegration of the tumor's vascular network.

It is perhaps surprising that the Flk-1 vaccine can mediate tumor vessel destruction without causing significant problems during pregnancy and wound healing (Figure 5). However, angiogenesis during tumor development differs significantly from the highly organized, slow growth of wound healing or the uterine NK cell driven angiogenesis and spiral artery formation seen during implantation and placenta development (51). We hypothesize that rapid vessel formation, and unorganized and improper development of vascular networks associated with poor pericyte coverage in tumors increases the susceptibility of tumor tissue to anti-angiogenesis therapy. In addition, tissue specificity and cells involved in tumor vessel recruitment differs from superficial wounds, although many similarities still exist (52). For instance, the inflammatory environment for an invasive tumor is similar for cell types and cytokines involved in wound repair. However, the rate of new vessel growth and sheer numbers of trafficking leukocytes is greater for tumors (52).

Commercialized anti-angiogenesis immunotherapies have mainly been restricted to antibodies binding either VEGF-A or VEGFRs; several non-immunotherapies have targeted inhibiting the downstream function of key receptors (e.g., VEGFR1/2, PDGFR)

such as Sorafenib (Nexavar®). However, several experimental forms of anti-angiogenic immunotherapy are either in preclinical or clinical development. These include the use of whole fixed endothelial cells (53), VEGFR2-conjugated proteins (54), pulsed dendritic cells (55), liposomal peptide for FGF-2 (56), and several DNA vaccines immunizing against survivin, integrin  $\beta$ 3, VEGF, VEGFR2 (see review (57)), and even live vaccine vectors used as shuttles for DNA vaccines against VEGFR2 and Endoglin/CD105 (16, 58).

Using immunotherapy to target the vasculature presents several advantages over the passive administration of purified antibodies, one being the ability to boost the initial immune response overtime and the cost of vaccination. However, presented here, is the novel use of a recombinant fusion protein expressing *Listeria monocytogenes* vector, which presents several advantages over the use of other bacterial vectors. Our Lm-LLO-Flk-1 strains increase the immunogenicity of the Flk-1 fragment via fusion to LLO, are highly attenuated and primarily replicate within macrophages and dendritic cells. Both the inflammatory response to infection with *Listeria* and the additional responses induced by our fusion protein constructs have the power to simultaneously reduce T regulatory cell numbers at the site of the tumor while inducing potent anti-tumor CTLs (23).

Metastatic breast cancer is especially susceptible to anti-angiogenesis treatment because metastases need to recruit new vessels when becoming established at distant locations from the primary tumor site (45). Several clinical studies suggest that micrometastases can exist in a growth static state at around 1-3 mm in diameter and feed from the passive movement of molecules. However, to support tumor growth beyond 3mm, the new synthesis of a vascular network is required (46). It is at this point that we anticipate the maximum benefit from our anti-VEGFR2 vaccines, which may possibly blunt the spread of metastatic breast cancer.

### ***Acknowledgements***

We would like to give a special thanks to Drs. Ellen Pure for the 4T1-Luc cells and Ralph Reisfeld for the original Flk-1 plasmid. The imaging data presented here was performed

at the Optical Imaging Core of the Small Animal Imaging Facility (SAIF) at the University of Pennsylvania. We are also grateful to Dr. Yingqui Yvette Liu and Dr. Wafik S. El-Deiry for their advice and assistance on the part of the optical imaging study.

## REFERENCES

1. Si, Z. C., and J. Liu. 2008. What "helps" tumors evade vascular targeting treatment? *Chinese medical journal* 121:844-849.
2. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. *The New England journal of medicine* 285:1182-1186.
3. Widakowich, C., P. Dinh, E. de Azambuja, A. Awada, and M. Piccart-Gebhart. 2008. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? *Anti-cancer agents in medicinal chemistry* 8:488-496.
4. Esteva, F. J. 2004. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. *The oncologist* 9 Suppl 3:4-9.
5. Hida, K., Y. Hida, and M. Shindoh. 2008. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. *Cancer science* 99:459-466.
6. Jain, R. K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science (New York, N.Y)* 307:58-62.
7. Bergers, G., and D. Hanahan. 2008. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer* 8:592-603.
8. Noonan, D. M., A. De Lerma Barbaro, N. Vannini, L. Mortara, and A. Albini. 2008. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. *Cancer metastasis reviews* 27:31-40.
9. Folkman, J. 1997. Angiogenesis and angiogenesis inhibition: an overview. *Exs* 79:1-8.
10. Eberhard, A., S. Kahlert, V. Goede, B. Hemmerlein, K. H. Plate, and H. G. Augustin. 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. *Cancer research* 60:1388-1393.
11. Maciag, P. C., Seavey, M.M., Pan, Zhen-Kun, Ferrone, S., Paterson, Y. 2008. Cancer immunotherapy targeting the HMW-MAA protein results in a broad anti-tumor response and reduction of pericytes in the tumor vasculature. *Cancer research* in press.
12. Shalaby, F., J. Ho, W. L. Stanford, K. D. Fischer, A. C. Schuh, L. Schwartz, A. Bernstein, and J. Rossant. 1997. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. *Cell* 89:981-990.
13. Yamaguchi, T. P., D. J. Dumont, R. A. Conlon, M. L. Breitman, and J. Rossant. 1993. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. *Development (Cambridge, England)* 118:489-498.
14. Millauer, B., S. Wizigmann-Voos, H. Schnurch, R. Martinez, N. P. Moller, W. Risau, and A. Ullrich. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. *Cell* 72:835-846.
15. Millauer, B., M. P. Longhi, K. H. Plate, L. K. Shawver, W. Risau, A. Ullrich, and L. M. Strawn. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. *Cancer research* 56:1615-1620.
16. Niethammer, A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Pertl, G. Karsten, B. P. Eliceiri, and R. A. Reisfeld. 2002. A DNA vaccine against VEGF receptor 2

- prevents effective angiogenesis and inhibits tumor growth. *Nature medicine* 8:1369-1375.
17. Luo, Y., D. Markowitz, R. Xiang, H. Zhou, and R. A. Reisfeld. 2007. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. *Vaccine* 25:1409-1415.
  18. Folkman, J. 1996. Tumor angiogenesis and tissue factor. *Nature medicine* 2:167-168.
  19. Shibuya, M. 2006. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. *Endothelium* 13:63-69.
  20. Strawn, L. M., G. McMahon, H. App, R. Schreck, W. R. Kuchler, M. P. Longhi, T. H. Hui, C. Tang, A. Levitzki, A. Gazit, I. Chen, G. Keri, L. Orfi, W. Risau, I. Flamme, A. Ullrich, K. P. Hirth, and L. K. Shawver. 1996. Flk-1 as a target for tumor growth inhibition. *Cancer research* 56:3540-3545.
  21. Taraboletti, G., and B. Margosio. 2001. Antiangiogenic and antivascular therapy for cancer. *Current opinion in pharmacology* 1:378-384.
  22. Seavey, M. M., Verch, T., Paterson, Y. 2008. Handbook of Listeria Monocytogenes; Chapter 16: Anticancer Vaccine Strategies. *Editor: Dongyou Liu*
  23. Hussain, S. F., and Y. Paterson. 2005. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. *Cancer Immunol Immunother* 54:577-586.
  24. Singh, R., M. E. Dominiacki, E. M. Jaffee, and Y. Paterson. 2005. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. *J Immunol* 175:3663-3673.
  25. Sewell, D. A., V. Shahabi, G. R. Gunn, 3rd, Z. K. Pan, M. E. Dominiacki, and Y. Paterson. 2004. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. *Cancer research* 64:8821-8825.
  26. Bruhn, K. W., N. Craft, and J. F. Miller. 2007. Listeria as a vaccine vector. *Microbes and infection / Institut Pasteur* 9:1226-1235.
  27. Pan, Z. K., L. M. Weiskirch, and Y. Paterson. 1999. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. *Cancer research* 59:5264-5269.
  28. Gunn, G. R., A. Zubair, C. Peters, Z. K. Pan, T. C. Wu, and Y. Paterson. 2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. *J Immunol* 167:6471-6479.
  29. Shahabi, V., M. Reyes-Reyes, A. Wallecha, S. Rivera, Y. Paterson, and P. Maciag. 2008. Development of a Listeria monocytogenes based vaccine against prostate cancer. *Cancer Immunol Immunother*.
  30. Brockstedt, D. G., M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Lockett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. *Proceedings of the National Academy of Sciences of the United States of America* 101:13832-13837.

31. Bruhn, K. W., N. Craft, B. D. Nguyen, J. Yip, and J. F. Miller. 2005. Characterization of anti-self CD8 T-cell responses stimulated by recombinant *Listeria monocytogenes* expressing the melanoma antigen TRP-2. *Vaccine* 23:4263-4272.
32. Brockstedt, D. G., and T. W. Dubensky. 2008. Promises and challenges for the development of *Listeria monocytogenes*-based immunotherapies. *Expert review of vaccines* 7:1069-1084.
33. Edelson, B. T., and E. R. Unanue. 2001. Intracellular antibody neutralizes *Listeria* growth. *Immunity* 14:503-512.
34. Mata, M., Z. J. Yao, A. Zubair, K. Syres, and Y. Paterson. 2001. Evaluation of a recombinant *Listeria monocytogenes* expressing an HIV protein that protects mice against viral challenge. *Vaccine* 19:1435-1445.
35. Maciag, P. C., M. M. Seavey, Z. K. Pan, S. Ferrone, and Y. Paterson. 2008. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. *Cancer research* 68:8066-8075.
36. Yunbham, M. K. 1998. Inhibition of breast cancer in nude mouse model by anti-angiogenesis. *Oncology reports* 5:1431-1437.
37. Shimizu, M., M. Shimamura, T. Owaki, M. Asakawa, K. Fujita, M. Kudo, Y. Iwakura, Y. Takeda, A. D. Luster, J. Mizuguchi, and T. Yoshimoto. 2006. Antiangiogenic and antitumor activities of IL-27. *J Immunol* 176:7317-7324.
38. Gyorffy, S., K. Palmer, T. J. Podor, M. Hitt, and J. Gauldie. 2001. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. *J Immunol* 166:6212-6217.
39. Singh, R., and Y. Paterson. 2007. Immunoediting sculpts tumor epitopes during immunotherapy. *Cancer research* 67:1887-1892.
40. Singh, R., and Y. Paterson. 2006. Vaccination strategy determines the emergence and dominance of CD8<sup>+</sup> T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. *Cancer research* 66:7748-7757.
41. Singh, R., and Y. Paterson. 2007. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by *Listeria monocytogenes*-based vaccines. *Cancer Immunol Immunother* 56:927-938.
42. Rubocki, R. J., D. R. Lee, W. R. Lie, N. B. Myers, and T. H. Hansen. 1990. Molecular evidence that the H-2D and H-2L genes arose by duplication. Differences between the evolution of the class I genes in mice and humans. *The Journal of experimental medicine* 171:2043-2061.
43. Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J. P. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. *The Journal of experimental medicine* 201:1591-1602.
44. Manning, E. A., J. G. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens. 2007. A vascular

- endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. *Clin Cancer Res* 13:3951-3959.
45. Augustin, H. G. 1998. Antiangiogenic tumour therapy: will it work? *Trends in pharmacological sciences* 19:216-222.
  46. Heidenreich, R., A. Kappel, and G. Breier. 2000. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. *Cancer research* 60:6142-6147.
  47. Pulaski, B. A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. *Current protocols in immunology / edited by John E. Coligan ... [et al Chapter 20:Unit 20 22.*
  48. Matthew M. Seavey, Z.-K. P., Paulo C. Maciag, Anu Wallecha, Sandra Rivera, Yvonne Paterson, Vafa Shahabi. 2008. A Novel Human Her-2/neu Chimeric Molecule Expressed by *Listeria monocytogenes* Can Elicit Potent HLA-A2 Restricted CD8+ T cell Responses and Impact the Growth and Spread of Her-2/neu + Breast Tumors. *Clin Cancer Res* in press.
  49. Hatake, K., N. Tokudome, and Y. Ito. 2007. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. *Breast cancer (Tokyo, Japan)* 14:132-149.
  50. Korkkaya, H., A. Paulson, F. Iovino, and M. S. Wicha. 2008. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. *Oncogene*.
  51. Leonard, S., C. Murrant, C. Tayade, M. van den Heuvel, R. Watering, and B. A. Croy. 2006. Mechanisms regulating immune cell contributions to spiral artery modification -- facts and hypotheses -- a review. *Placenta* 27 Suppl A:S40-46.
  52. Schafer, M., and S. Werner. 2008. Cancer as an overhealing wound: an old hypothesis revisited. *Nat Rev Mol Cell Biol* 9:628-638.
  53. Wei, Y. Q., Q. R. Wang, X. Zhao, L. Yang, L. Tian, Y. Lu, B. Kang, C. J. Lu, M. J. Huang, Y. Y. Lou, F. Xiao, Q. M. He, J. M. Shu, X. J. Xie, Y. Q. Mao, S. Lei, F. Luo, L. Q. Zhou, C. E. Liu, H. Zhou, Y. Jiang, F. Peng, L. P. Yuan, Q. Li, Y. Wu, and J. Y. Liu. 2000. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. *Nature medicine* 6:1160-1166.
  54. Liu, J. Y., Y. Q. Wei, L. Yang, X. Zhao, L. Tian, J. M. Hou, T. Niu, F. Liu, Y. Jiang, B. Hu, Y. Wu, J. M. Su, Y. Y. Lou, Q. M. He, Y. J. Wen, J. L. Yang, B. Kan, Y. Q. Mao, F. Luo, and F. Peng. 2003. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. *Blood* 102:1815-1823.
  55. Li, Y., M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen, and D. J. Hicklin. 2002. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. *The Journal of experimental medicine* 195:1575-1584.
  56. Plum, S. M., J. W. Holaday, A. Ruiz, J. W. Madsen, W. E. Fogler, and A. H. Fortier. 2000. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. *Vaccine* 19:1294-1303.

57. Okaji, Y., N. H. Tsuno, S. Saito, S. Yoneyama, M. Tanaka, H. Nagawa, and K. Takahashi. 2006. Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy. *Eur J Surg Oncol* 32:363-370.
58. Lee, S. H., N. Mizutani, M. Mizutani, Y. Luo, H. Zhou, C. Kaplan, S. W. Kim, R. Xiang, and R. A. Reisfeld. 2006. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. *Cancer Immunol Immunother* 55:1565-1574.

**Figure 1. Design of the Flk-1/VEGFR2 expressing *Lm*-based constructs**

**A**, Cloned regions for each construct built are boxed, mapped CTL epitopes for the H2<sup>d/q</sup> MHC I haplotype include: Flk<sub>210</sub> (TYQSIMYIV), Flk<sub>613</sub> (MFSNSTNDI), Flk<sub>906</sub> (PGGPLMVIV) and are shown in bold font (17). **B**, Each gene fragment was cloned into the expression vector pGG34 fused to LLO and placed under the control of the *hly* promoter. **C**, Western blot of proteins from culture supernatants showing expression of each fusion protein from the constructs listed. Polyclonal, rabbit, anti-PEST antibody was used for fusion protein detection (bottom), and mouse anti-LLO antibody was used for confirmation (top). Note that all lanes within a single blot were taken from the same Western blot; immunostaining was performed on two separate but identical blots. **D**, IFN $\gamma$  ELISpot showing CD8<sup>+</sup> T cell restricted responses *ex vivo* after immunization with each construct. The naive group was injected with PBS alone; all groups contained a control *Lm* group. Responses are to the corresponding mapped epitopes for each Flk fragment, pE1 = Flk-E1<sub>210-219</sub> (TYQSIMYIV), pE2 = Flk-E2<sub>613-622</sub> (MFSNSTNDI), pI1 = Flk-I1<sub>906-915</sub> (PGGPLMVIV), N=5 per group. Graphs show Mean $\pm$ SEM; \*p<0.05, Mann-Whitney statistical test, experiment repeated once.

**Figure 2. *Lm*-LLO-Flk-1 vaccines can induce regression of established Her-2/neu+ tumors *in vivo***

**A**, NT-2 tumor volume (mm<sup>3</sup>) from mice treated with each construct. Graph shows Mean $\pm$ SEM; \*p<0.05, Mann-Whitney statistical test, N=8 mice per group, experiment repeated twice. **B**, IFN $\gamma$  ELISpots showing epitope spreading to various Her-2/neu regions. Splenocytes from the 64-day time point were restimulated *ex vivo* with Her-2/neu peptide epitopes. Graph shows Mean $\pm$ SEM; \*p<0.05, Mann-Whitney statistical test, N=5 mice per group, experiment repeated once. **C**. Mice that had fully regressed tumors were re-challenged with NT-2 in the contra-lateral flank on day 100. A saline treated group was used as our negative control for tumor growth. **D**. Tumor volume for mice that grew tumors after re-challenge on day 100 of tumor free mice. Both graphs refer to a single experiment. Number of tumor free mice was 2/8 for Flk-E1 and Flk-I1

groups, the saline group had 5 mice. **E**, Mice were immunized thrice over the course of three weeks after the initial establishment of NT-2 tumors. In this figure (right hand panel) we show staining for the pan-endothelial marker CD31-PE and nucleus using DAPI. Isotype controls were used on sequential sections as shown to the right. Quantitation of vessel density, shown in the left hand panel, was performed using Image Pro software. Graph shows Mean±SEM, \*p<0.05, Mann-Whitney test, ns = not significant.

**Figure 3. Anti-angiogenesis vaccines are not effective in mice tolerant to HER-2/neu**

**A**, FVB/N wild-type (WT) or FVB/N transgenic (Tg) mice were injected with  $1 \times 10^6$  NT-2 cells s.c., tumors were allowed to grow until palpable before treatment started. Mice were immunized a total of three times, mean tumor sizes are shown here for up to 69 days post tumor inoculation. Graphs show Mean±SEM; \*p<0.05, Mann-Whitney test, experiment repeated twice. **B**, Spleens were processed for IFN $\gamma$  ELISpots, stimulated with various Her-2/neu peptides *ex vivo*, or a third party peptide as a negative control (pGag). Graphs show Mean±SEM; \*p<0.05, Mann-Whitney test, experiment repeated once. **C**, Tumors from each group were pooled and digested for TILs; here we show Her-2/neu specific T cells staining for CD8 $\alpha$  and EC1 or IC1 specific tetramers. Significantly more Her-2/neu specific T cells are found in the wild type (WT) but not transgenic (Tg) mice; control *Lm* group shows low background. Experiment repeated once giving similar results.

**Figure 4. Flk-1 vaccines can protect mice from experimental metastases and induce weak Her-2/neu epitope spreading in a more aggressive tumor model for breast cancer**

**A**, Mice were immunized thrice with each vaccine then injected with 50,000 4T1 cells i.v., tumors were allowed to grow for 25 days then mice were sacrificed. H+E stained sections were performed on lung tissues, tumor nodes were counted by hand. Graph shows the number of lung metastases per lobe per animal, Mean±SEM; \*p<0.05, Mann-Whitney test, experiment repeated once, N=5 mice shown. **B**, Spleens from these animals were processed and re-challenged *ex vivo* in IFN $\gamma$  ELISpot assays for Her-2/neu

epitope spreading. The 4T1 cell line does express low levels of mouse Her-2/neu (48). Spreading is seen only in the Flk-1-E1 immunized mice. Graph shows Mean±SEM for spot number per well as compared to control *Lm* group; \*p<0.05, Mann-Whitney test, experiment repeated once, N=5 per group. **C**, A similar experiment where mice were protected via immunization with each vaccine for a series of three weeks then injected with 50,000 4T1-Luc cells i.v.; mice were imaged longitudinally over the course of four weeks looking for the incidence of lung seeding and rate of metastasis (top panel). Average radiance in photons (p) captured per second (s) per cm<sup>2</sup> for the surface area (sr) gated in the ROI is shown in the bottom panel. Graph shows Mean±SEM; \*p<0.05, Mann-Whitney test. Significance for mice as follows: Day 18, only Flk-E1 significant; Day 25, both Flk-E1 and Flk-I1 significantly different when compared to control *Lm*. **D**. Primary subcutaneous 4T1 tumors grow slower in *Lm*-LLO-Flk-1 protected animals. Mice were immunized thrice with each vaccine then injected with s.c. and i.v. with 50,000 4T1 cells. Graph shows Mean±SEM for tumor volume.

**Figure 5. Safety studies using the anti-angiogenesis Flk-1 vaccines**

Mice were immunized thrice as performed in all previous experiments then were allowed to either mate or entered into wound-healing studies. **A**, Mice (n=5/group) were mated with syngeneic FVB/N males, gestation was confirmed upon the observance of a vaginal plug following coitus. This was considered as day 0.5dpc. Total gestation length, pup mass at term, and total litter size was measured, graphs show Mean±SEM; \*p<0.05. **B**, A pair of sterile skin biopsies were produced on the back of each vaccinated mouse (N=5/group). Healing was observed on a daily basis. On day 14 healing was complete for all groups tested, near identical healing was observed for all groups. Graph shows the number of days until wound closure, Mean±SEM; \*p<0.05, Mann-Whitney test.

**Figure 6.0. Flk-1 vaccine induced epitope spreading may not be due to cross reactivity between Flk-1 and Her-2/neu shared domains**


Mice were immunized thrice with either control *Lm* or Flk-I1 vaccine. Splenocytes were processed and re-challenged *ex vivo* for the secretion of IFN $\gamma$  in response to peptide challenge. Peptides included were the previously mapped pFlk-I1 epitope

(PGGPLMVIV), a putative pIC1 epitope for Her-2/neu (GSGAFGTVYK) or the epitope in question, a putative shared epitope between the Her-2/neu and Flk-1 kinase domains (GRGAFGQVI), and a third party epitope used as a negative control (pGag). Graph shows Mean $\pm$ SEM, N=3/group.


A.

ME SKALLAVALWFCVYETRAASVGLPGDFLHPKPSFKDKLTLANTLQTCRGGRLD91LWPN  
 AQRDSELRVAVTECGGGDSHFCKTLTPKRVGNDTGAVCYSYRVDVIASTVYVYVRDYSRPLASV  
 SIQRGIVYITENKMKVTVVHRCGSSNLSVSLCARYPKRPFVGGNRKSKPDRGFTLPSYMSYAG  
 MVVCTAKINDETLQNMIVVYVGYRVDVLSPPHFIISAGIKVLIACARTELNAGLDFTWIS  
 PPSAHHKAVNRPVKPPGTVAKMFLSTLIESYTKSDQGYTCVASSGRMIKRNKTPVSKVIEKP  
 FIAFGSGMKSVEATVGSQVRIPVYLYVFAPIKWRVNRGRFESNYTMDGDELIMBVTERTDAG  
 NYTVLTPNISMEEKQSHMVSIVVNNPFGREKALISPMDSYCYGTGQTLCTVYANPFLHHDQWY  
 WQLEAACYSRPGQTSPYACKEWRIHVEDPQGGNKIEVTKNQYALIEGKNKTVSTLVQAANVSAL  
 YKCAINKAGRGGRVSYFVIRGPELITVQPAAGQTEQSSNLLCTADINTFNLTRYKLLGQATSVL  
 HMGEISLTPVCKNLDALWKLNGTMSNSTNMLIVAFQNASIQDQGYVCSA/DKATKAKHCLV  
 KQILERMAPMITGNLENQITITGRTVTCFASGNPPIHTWFKQINTELVFDSGVIKQGNKSLT  
 RVRKFDKGLYTCQACNVLGCARAETLHIGAGAKTMSVIEVIGTAVLAMPFWLLVIVLRTVK  
 RANDELKTDYLSVMDPDELPLDERICERLPIYDASKWTFPRRRLKLGKPLGRGAFGCVEADAFG  
 DKLATECKYAVKMLKGGATDSIRHIALMSLKIILHGHIBLNVNLLGACTPGGPIMLIEFCKL  
 FGNLSTYLRKAKNITVYPKSKGARFRQGDYVGLSVDLAKRLDSITSQSSASSGPFVLEKLSQV  
 FEEIASSELYKEDTLFHLVYSSQAGMFLASKKCHRELAARNLLSKNVAKYCDFGLARDI  
 YKQDPYVRKGDARPLKAWMAPEITHDQVYTGQSDVWSFGVLLWEPFLSASPYGNKVIDEFCRR  
 LKFGTRMRAPDYTFPMVQTMLDCAWHIDPNQRPSISLVEHGNLQANAQDQGDYVLPMSI  
 TLMSEEDSGLSPTSPVSCMEEIEVCDPKFHYDNTAGISHYLQNSKRSRPSVAKTFEDPLEEPV  
 KVIPDSQTDGMPGLASEELKTLDRNKLSPSGMMPKASRESVASEGNSQYSGYQGYHSDDT  
 DITVYSSDEAGLLKMDVAHVHADSGLTILRSPPV


B.











C.





D.









A.




B.



C.



Average Radiance



D.

